Great Point Partners LLC Takes $14.88 Million Position in Context Therapeutics Inc. (NASDAQ:CNTX)

Great Point Partners LLC acquired a new position in Context Therapeutics Inc. (NASDAQ:CNTX) in the second quarter, HoldingsChannel.com reports. The firm acquired 7,419,355 shares of the company’s stock, valued at approximately $14,876,000. Context Therapeutics comprises about 2.8% of Great Point Partners LLC’s investment portfolio, making the stock its 15th largest holding. Great Point Partners LLC owned approximately 0.10% of Context Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Ally Bridge Group NY LLC increased its holdings in shares of Context Therapeutics by 159.8% in the 2nd quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after purchasing an additional 1,160,281 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after buying an additional 25,300 shares in the last quarter. Finally, Opaleye Management Inc. raised its position in Context Therapeutics by 13.7% in the 1st quarter. Opaleye Management Inc. now owns 1,108,357 shares of the company’s stock worth $1,530,000 after buying an additional 133,357 shares during the last quarter. 14.03% of the stock is owned by institutional investors.

Context Therapeutics Stock Performance

CNTX stock opened at $2.08 on Tuesday. The company has a market cap of $156.00 million, a price-to-earnings ratio of -1.56 and a beta of 2.31. The business’s 50-day moving average is $2.31 and its two-hundred day moving average is $1.89. Context Therapeutics Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. Equities analysts predict that Context Therapeutics Inc. will post -0.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Context Therapeutics in a research report on Monday.

Context Therapeutics Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.